Cannabidiol After Multi-Trauma for Pain and Opioid Therapy

Fracture Clinical Trial

— CAM-POT  

Official title:

Effects of an Acute 1-month Cannabidiol Treatment on Pain and Inflammation After a Long Bone Fracture: a Triple-blind Randomized, Placebo Controlled Clinical Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06448923
• Other study ID #: 2025-2105
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: July 2024
• Est. completion date: July 2026

Study information

• Verified date: June 2024
• Source: Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
• Contact: Louis De Beaumont, PhD
• Phone: 514-338-2222
• Email: louis.de.beaumont[@]umontreal.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this project is to investigate the therapeutic potential and safety of acute Cannabidiol (CBD) treatment on longitudinal pain symptoms, and to assess potential interactions with pain mediators including opioids and sex on CBD treatment response. To this end, this research protocol proposes a comprehensive translational approach including a placebo-controlled randomized clinical trial comparing two daily doses of CBD treatment administered for one month on pain relief. This study will also compare intervention conditions on inflammation markers, participant quality of life, sleep quality, depression, anxiety, cognition and orthopaedic function.

Description:

The level of pain in the acute phase after injury is a predictor of the development of chronic pain. Chronic pain is defined as pain that persists for more than 3 months post-accident and impairs functional recovery. Mechanistically, it has been shown that acute nonspecific inflammation triggered after peripheral injury results in the continuous release of proinflammatory cytokines that weaken the blood-brain barrier, facilitating the entry of toxins that can invade the central nervous system (CNS). The resulting sustained inflammation of the CNS plays an important role in establishing the maladaptive plasticity process underlying pain chronification. Cannabidiol (CBD), a component of cannabis devoid of addictive or psychotropic effects, stands out as a potential therapeutic agent given its analgesic and anti-inflammatory properties as well as its potential to enhance the biomechanical properties of bone healing. Given the excellent safety profile of CBD and its inhibitory effects on microglial activity, the primary mechanism of neuroinflammation and pain, CBD has the potential to promote acute pain relief while reducing reliance on addictive opioid treatments, hence facilitating recovery in trauma patients.

This study is a randomized, placebo controlled, human pilot clinical trial evaluating the effects of two doses (low and moderate) of CBD vs. placebo on pain after orthopaedic trauma.

Risks of adverse effects are considered low given the demonstrated excellent safety profile of CBD. CBD was also shown to accentuate opioid analgesic effects, thus reducing required opioid doses for patient comfort. The most likely adverse events associated with CBD in adult patients include somnolence, fatigue, drowsiness and decreased appetite. Access to on-duty emergency physicians at the recruiting site will be provided during the entire treatment duration.

A 30 percent relative pain intensity reduction on the Visual Analog Scale (VAS) (expected response of 50 percent or more in the CBD group and expected 20 percent in the placebo group) has been used extensively to reflect clinically significant pain relief in clinical trials. Based on a Fisher's exact test, a sample size of 168 participants (3 groups of 56) will be required to reach a power of 80 percent to detect a statistically significant difference in the proportion of patients who reaches 30 percent pain reduction between the CBD groups and placebo at 1-month post-injury, assuming a dropout rate of 20 percent and a significance level of 5 percent. These parameters are taken from a successful randomised, placebo-controlled clinical trial using Sativex© in treating 125 neuropathic pain patients.

Our group has ensured the feasibility of conducting such a pilot clinical trial in multi-trauma patients with the recruitment of 110 patients in less than 18 months to take part in a 10-session, outpatient treatment trial. A partnership with Canadian company EmpowerPharm will enable the use of pharmaceutical-grade synthetic CBD samples and identical placebos. The pharmacokinetic profile of the CBD product has been established.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 168
• Est. completion date: July 2026
• Est. primary completion date: July 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Patients admitted to the Hopital du Sacre-Coeur de Montreal (HSCM), within 72h of the accident for a long bone fracture with or without mTBI

• Subject has provided informed consent

• Subject is between 18 and 70 years old

Exclusion Criteria:

• Moderate/severe traumatic brain injury (TBI)

• Diagnosis of any of the following mental disorders as defined by the DSM-5:

schizophrenia, intellectual deficiency, bipolar disorder, major depression, undiagnosed and untreated sleep disorders

• History of alcohol or opioid misuse/abuse

• Evidence of severe renal (stage 4 or 5) or hepatic impairment (stage B or C)

• Pregnant or lactating women, women of childbearing potential who are not using medically accepted forms of contraception, or women who are planning on becoming pregnant

• History of adverse reactions to cannabis

• Patients taking warfarin, sildenafil, valproate or under opioids treatment prior to the injury

• Patients experiencing on average mild-to-absent pain in the last 24h preceding recruitment (as per a score <30 on a 0-100mm Visual Analogue Scale (VAS))

• Transport business drivers and heavy machinery operators

• A diagnosis of chronic pain, bone pathology (osteoporosis) or chronic inflammatory disease (rheumatoid arthritis, arthritis, psoriasis)

• Not have French or English as a spoken language

• A weighted MoCA score of less than 24

• Regular cannabis use of more than 5 times a week

Related Conditions & MeSH terms

• Fracture
• Fractures, Bone

Intervention

Drug:
• Cannabidiol
25 mg of CBD tablets twice daily
• Cannabidiol
50 mg of CBD tablets twice daily
• Placebo
Matching placebo tablets twice daily

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pain catastrophization using the Pain Catastrophizing Scale	The Pain Catastrophizing Scale is a 15-item self-report questionnaire assessed with Likert Scales. The overall score has a range of 0-52, with higher scores representing more severe symptoms.	Baseline
Other	Change in mTBI symptoms resolution using the Rivermead Post-Concussion Questionnaire (RPQ)	Only for participants diagnosed with mTBI related to the injury. The RPQ has a total possible score of 0-52, with higher scores indicative of worse outcomes.	Baseline, 4 weeks and 3 months
Other	Treatment Expectation using the Treatment Expectation Questionnaire (TEX-Q-F)	The Treatment Expectation Questionnaire is a 15-item questionnaire assessing the level of expectation towards treatment. The scale of the items ranges from 0 to 10. Higher scores indicate higher expectations.	Baseline
Other	Symptoms of Post-Traumatic Stress Disorder using the PTSD Checklist for DSM-5 (PCL-5) questionnaire	The PTSD Checklist for DSM-5 (PCL-5) is a 20-item self-report measure of the Diagnostic and Statistical Manual (DSM-5) symptoms of PTSD. Scores range from 0 to 80, with higher scores representing more severe symptoms of PTSD.	Baseline and 4 weeks
Primary	Change From Baseline on Pain Intensity Rating on a Visual Analog Scale (VAS) at Week 4	VAS pain intensity will be collected at baseline (before the start of treatment), twice a week during treatment, 24 hours after the end of treatment and at the 3-month follow-up. The VAS is a 100 mm line with anchor words ranging from "no pain" to "worst pain imaginable". Participants will be asked to place an intersecting mark along the line to indicate their pain intensity at the specific time of the test.	Baseline and 4 weeks
Secondary	Response Rate - 50 Percent or Greater Reduction in Pain Intensity on a Visual Analog Scale (VAS)	The response rate was defined as the number of participants with a 50 percent or greater reduction in VAS pain score from baseline to end of treatment. The VAS is a 100 mm line with anchor words ranging from "no pain" to "worst pain imaginable".	4 weeks
Secondary	Change in Pain Rating on the Brief Pain Inventory Short Form (BPI-sf) Between Interventions	The Brief Pain Inventory short form (BPI-sf) is a 9-item self-reported questionnaire assessing for the presence, intensity, and location(s) of pain, as well as perceived efficacy of pain relief treatment, and pain interference with activities of daily living. Item scores range from 0-10. The lower the score, the better the subject's pain.	4 weeks and 3 months
Secondary	Change in Blood Level Inflammation Over Time and Between Interventions	Blood levels of pro-inflammatory cytokines including interleukins (IL-6, IL-10) and tumor necrosis factor-alpha (TNF-a) will be collected and quantified.	Baseline, 4 weeks and 3 months
Secondary	Opioid Usage Monitoring	Opioid usage will be collected from daily medication diary for the first month and from number of prescription refills for months 2 and 3.	Ongoing from baseline to 3 months
Secondary	Change in the Orthopaedic Function Using The Short Musculoskeletal Function Assessment (SMFA) Questionnaire Between Interventions	The SMFA consists of 34 questions covering the assessment of the patients function and 12 questions related to how bothered patients are by their symptoms. All categories are scored together, totaling between 0-100 percent. The lower the score, the better the subject's function.	4 weeks and 3 months
Secondary	Change in Quality of Life Using the Short Form (36) Health Survey Between Interventions	The SF-36 is a 36-item self-report questionnaire for measuring quality of life across 9 domains. Scores range from 0-100, the lower the score, the worse is the subject's quality of life.	4 weeks and 3 months
Secondary	Change in Sleep Quality Using the Pittsburgh Sleep Quality Index (PSQI) Between Interventions	A self-report questionnaire that assesses sleep quality and quantity during the past 4 weeks. The PSQI contains 19 self-rated questions which measures seven aspects of sleep: (1) subjective sleep quality, (2) sleep latency, (3) sleep duration, (4) habitual sleep efficiency, (5) sleep disturbances, (6) use of sleeping medication, and (7) daytime dysfunction. The 19 self-rated items are combined to form seven component scores, each of which has a range of 0-3 points (0 indicates no difficulty, while 3 indicates severe difficulty). The seven component scores are then summed to yield one global score, with a range of 0-21 points (0 indicating no difficulty, and 21 indicating severe difficulties in all the seven areas of sleep quality).	4 weeks and 3 months
Secondary	Change in Depression Symptoms Assessment Using the Beck's Depression Inventory-II Between Interventions	A 21-item multiple-choice self-report questionnaire for measuring depression symptoms. Scores range from 0 to 63, with higher scores representing more severe symptoms of depression.	Baseline, 4 weeks and 3 months
Secondary	Change in Anxiety Symptoms Assessment Using the Beck's Anxiety Inventory Between Interventions	A 21-question multiple-choice self-report inventory used for measuring the severity of anxiety symptoms. Score range from 0 to 63. Higher scores indicate more severe anxiety symptoms.	Baseline, 4 weeks and 3 months
Secondary	Change in Speed of Information Processing using Symbol Search from the WAIS-IV Battery Between Intervention	A neuropsychological test highly sensitive to both mild traumatic brain injury (mTBI) and pain and which do not require the use of injured limbs will be administered. Symbol Search from the WAIS-IV Battery, a tasks assessing speed of information processing, will be administered. Scaled Score range from 0 to 19. Higher scores indicate better processing speed.	Baseline, 4 weeks and 3 months
Secondary	Change in Attention using Elevator counting with distraction from the Test of Everyday Attention Battery Between Intervention	A neuropsychological test highly sensitive to both mild traumatic brain injury (mTBI) and pain and which do not require the use of injured limbs will be administered. Elevator counting with distraction from the Test of Everyday Attention Battery, a tasks assessing attention, will be administered. Scaled Score range from 0 to 19. Higher scores indicate better attention.	Baseline, 4 weeks and 3 months
Secondary	Change in Attention using Elevator counting from the Test of Everyday Attention Battery Between Intervention	A neuropsychological test highly sensitive to both mild traumatic brain injury (mTBI) and pain and which do not require the use of injured limbs will be administered. Elevator counting from the Test of Everyday Attention Battery, a tasks assessing attention, will be administered. Scaled Score range from 0 to 19. Higher scores indicate better attention.	Baseline, 4 weeks and 3 months
Secondary	Change in Memory using the California Verbal Learning Test Between Interventions	A neuropsychological test highly sensitive to both mild traumatic brain injury (mTBI) and pain and which do not require the use of injured limbs will be administered. The California Verbal Learning Test, a tasks assessing memory, will be administered. Standard Score range from -5 to 5. Higher scores indicate better memory.	Baseline, 4 weeks and 3 months
Secondary	Change in Memory using Digit Span from the WAIS-IV Battery Between Intervention	A neuropsychological test highly sensitive to both mild traumatic brain injury (mTBI) and pain and which do not require the use of injured limbs will be administered. Digit Span from the WAIS-IV Battery, a tasks assessing memory, will be administered. Scaled Score range from 0 to 19. Higher scores indicate better memory.	Baseline, 4 weeks and 3 months
Secondary	Change in Executive Fonction using the D-KEFS Color-Word Between Interventions	A neuropsychological test highly sensitive to both mild traumatic brain injury (mTBI) and pain and which do not require the use of injured limbs will be administered. The D-KEFS Color-Word, a tasks assessing executive function, will be administered. Scaled Score range from 1 to 19. Higher scores indicate better executive function.	Baseline, 4 weeks and 3 months
Secondary	Change in Executive Function using the D-KEFS Verbal Fluency Between Interventions	A neuropsychological test highly sensitive to both mild traumatic brain injury (mTBI) and pain and which do not require the use of injured limbs will be administered. The D-KEFS Verbal Fluency, a tasks assessing executive function, will be administered. Scaled Score range from 1 to 19. Higher scores indicate better executive function.	Baseline, 4 weeks and 3 months